The CEA Registry Blog

Nov 30

by CEA Registry Team 11/30/2011 5:06 PM  RssIcon

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1. Tu HA, Rozenbaum MH, Coyte PC, et al. Health economics of rotavirus immunization in Vietnam: Potentials for favorable cost-effectiveness in developing countries. Vaccine. 2011 Nov 22. [Epub ahead of print] PubMed PMID: 22119590.

2. Moreno SG, Novielli N, Cooper NJ. Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation. J Heart Lung Transplant. 2011 Nov 22. [Epub ahead of print] PubMed PMID: 22115674.

3. Clement FM, Ghali WA, Rinfret S, et al. Economic evaluation of increasing population rates of cardiac catheterization. BMC Health Serv Res. 2011 Nov 24;11(1):324. [Epub ahead of print] PubMed PMID: 22115423.

4. Naci H, de Lissovoy G, Hollenbeak C et al. Historical Clinical and Economic Consequences of Anemia Management in Patients with End-Stage Renal Disease on Dialysis Using Erythropoietin Stimulating Agents versus Routine Blood Transfusions: A Retrospective Cost-Effectiveness Analysis. J Med Econ. 2011 Nov 25. [Epub ahead of print] PubMed PMID: 22115328.

5. Honkoop PJ, Loymans RJ, Termeer EH, et al. Asthma control cost-utility randomized trial evaluation (ACCURATE): the goals of asthma treatment. BMC Pulm Med. 2011 Nov 24;11(1):53. [Epub ahead of print] PubMed PMID: 22114896.

6. Long EF. HIV Screening via Fourth-Generation Immunoassay or Nucleic Acid Amplification Test in the United States: A Cost-Effectiveness Analysis. PLoS One. 2011;6(11):e27625. Epub 2011 Nov 16. PubMed PMID: 22110698

7. Hawton A, Green C, Telford C, et al. The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D. Mult Scler. 2011 Nov 22. [Epub ahead of print] PubMed PMID: 22108867.

8. Liberato NL, Rognoni C, Rubrichi S, et al. Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis. Ann Oncol. 2011 Nov 21. [Epub ahead of print] PubMed PMID: 22104577.

9. Chen HW, Bercik RS, Werner EF, et al. Cost-Effectiveness of Percutaneous Tibial Nerve Stimulation Versus Extended Release Tolterodine for Overactive Bladder. J Urol. 2011 Nov 16. [Epub ahead of print] PubMed PMID: 22100006.

10. Neumann A, Schwarz P, Lindholm L. Estimating the cost-effectiveness of lifestyle intervention programmes to prevent diabetes based on an example from Germany: Markov modelling. Cost Eff Resour Alloc. 2011 Nov 18;9(1):17. [Epub ahead of print] PubMed PMID: 22099547.

11. Farshad M, Gerber C, Meyer DC, et al. Reconstruction versus conservative treatment after rupture of the anterior cruciate ligament: cost effectiveness analysis. BMC Health Serv Res. 2011 Nov 19;11(1):317. [Epub ahead of print] PubMed PMID: 22098703.

12. Nilsson FO, Linnér L, Samuelsson E, et al. Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry. BJU Int. 2011 Nov 17. [Epub ahead of print] PubMed PMID: 22093912.

13. Baker TM, Goh JW, Brown RE, et al. Cost-effectiveness Analysis of Valsartan versus Losartan and the Effect of Switching. J Med Econ. 2011 Nov 16. [Epub ahead of print] PubMed PMID: 22084957.

14. Watt M, Mealing S, Eaton J, et al. Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart. 2011 Nov 25. [Epub ahead of print] PubMed PMID: 22076021.

15. Gordon J, Lister S, Prettyjohns M, et al. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain. J Med Econ. 2011 Nov 17. [Epub ahead of print] PubMed PMID: 22017236.

By James D. Chambers


Your name:
Security Code
Enter the code shown above in the box below
Add Comment   Cancel 

Please view the blog archive for earlier entries

Search This Blog